On October 20, 2025, Keros Therapeutics, Inc. announced that it has commenced a cash tender offer to repurchase up to $194.4 million of its common stock at a purchase price of $17.75 per share. The offer is part of the company’s $375 million capital return program and will be funded from existing cash and cash equivalents.
The tender offer will expire at 5:00 p.m. ET on Tuesday, November 18, 2025, unless extended or terminated earlier. The company will make the offer only pursuant to an offer to purchase, letter of transmittal, and related documents that will be filed with the SEC upon commencement of the tender offer.
By repurchasing shares, Keros will reduce its shares outstanding, potentially increasing earnings per share and returning value to shareholders without incurring new debt. The program reflects the company’s commitment to capital discipline and shareholder value creation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.